Wave Life Sciences Ltd. (WVE) stock price, financials & research

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

43/100

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

53

Fair Value

Momentum

28

Weakening

Sentiment

64

Bullish

Risk resilience

42

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company’s medicines platform, PRISM combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; WVE-007, a GalNAc-conjugated small interfering RNA designed to silence INHBE mRNA targeting obesity; WVE-008, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of liver disease; WVE-N531, an exon splicing oligonucleotide for the treatment of Duchenne muscular dystrophy; and WVE-003, an allele-selective oligonucleotide for the treatment of Huntington’s disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was founded in 2012 and is based in Singapore.

Industry: Biotechnology
Sector: Healthcare
Headquarters: US
CEO: Paul Bolno
Listed since: Nov 11, 2015
Employees: 317

Market position

Day range

Current $5.29

$5.265$5.355

52-week range

Current $5.29

$5.01$21.73

Open: $5.32
Previous close: $5.25
Volume: 2.72M; 0.78× average
Average volume: 3.48M; Average daily volume
Market cap: 1.04B USD
Beta: -1.29; Market reference 1
50-day average: $5.8136; -9.01% below average
200-day average: $9.4283; -43.89% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value: 2.28B USD
P/E (TTM): -4.85×
P/B (TTM): 2.36×
P/S (TTM): 15.95×
EV / EBITDA: -11.67×
Earnings yield: -7.13%
Free cash flow yield: -6.54%
Dividend yield: 0.00%

Profitability & efficiency

Gross margin: 96.54%
Operating margin: -333.36%
Net margin: -309.73%
Return on equity: -38.84%
Return on assets: -32.01%
Return on invested capital: -39.03%

Financial health

Debt / equity: 0.1×
Current ratio: 6.47×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin

Income trends

Revenue

42.73M USD-60.55%

Operating income

−215.38M USD-95.09%

Net income

−204.38M USD-110.68%

Metric (USD)	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	42.73M USD	108.3M USD	113.31M USD	3.65M USD	40.96M USD
Cost of goods sold	8.85M USD	—	—	—	—
Gross profit	33.88M USD	108.3M USD	113.31M USD	3.65M USD	40.96M USD
Research and development	182.78M USD	159.68M USD	130.01M USD	115.86M USD	121.88M USD
Selling, general, and administrative	75.33M USD	59.02M USD	51.29M USD	50.51M USD	46.11M USD
Operating expenses	249.26M USD	218.71M USD	181.3M USD	166.37M USD	167.98M USD
Interest income	10.48M USD	—	—	—	30K USD
Depreciation and amortization	8.85M USD	8.66M USD	9.21M USD	10.11M USD	9.84M USD
Operating income	−215.38M USD	−110.4M USD	−68M USD	−162.72M USD	−127.02M USD
Net income	−204.38M USD	−97.01M USD	−57.51M USD	−161.82M USD	−122.25M USD